Agendia N.V. (AGDX)

Agendia will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Capn/a
Revenue (ttm)61.33M
Net Income (ttm)-30.86M
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About AGDX

Agendia is a mission-driven, commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide. Our solutions apply the power of functional genomic profiling to help physicians guide the care of women throughout their patient journey, from initial diagnosis to remission and cure, or recurrence and metastatic disease. Our scientific approach takes a holistic view of the biology unde...

IndustryHealth Care Providers & Services
Founded2003
CEOMark R. Straley
Employees248
Stock ExchangeNASDAQ
Ticker SymbolAGDX
Full Company Profile

Financial Performance

In 2020, Agendia's revenue was $57.89 million, an increase of 18.30% compared to the previous year's $48.94 million. Losses were -$19.97 million, -10.62% less than in 2019.

Financial Statements

News

Breast cancer diagnostics company Agendia files for a $75 million US IPO

Agendia, which provides genetic tests designed to guide optimal treatments for breast cancer, filed on Thursday with the SEC to raise up to $75 million in an initial public offering.

6 months ago - Renaissance Capital

Agendia IPO Registration Document (F-1)

Agendia N.V. has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC